January 23, 2024
This podcast episode features a conversation with Jason Foster, CEO of Ori Biotech, who discussed his varied career and insights into the biotech industry. Foster’s journey began in politics and healthcare policy in Washington, D.C., where he recognized the private sector’s crucial role in healthcare innovation. This realization spurred him to attend business school, leading to a significant role in a pharmaceutical company. His work there, marked by substantial growth, eventually took him to London to oversee European operations.
Foster’s career pivot to startups and healthcare investments reflects his passion for innovative healthcare solutions. He emphasizes the importance of assembling a strong team and the ability to solve complex problems in the startup environment. This approach is evident in his leadership at Ori Biotech, a company focused on revolutionizing cell and gene therapy manufacturing.
At Ori Biotech, Foster addresses the challenges of making advanced therapies accessible and affordable. He discusses the technological innovations and manufacturing strategies employed by Ori to streamline the production of these therapies. His vision is to democratize cell and gene therapies, making them available to a broader patient population.
The interview also delves into the broader implications of Ori Biotech’s work in the healthcare sector. Foster highlights the potential impact of their technology in transforming patient outcomes and reducing healthcare costs. He underscores the significance of collaboration between the private sector, academia, and regulatory bodies in advancing healthcare innovation.
About this Guest
Jason is a dynamic leader with over 20 years of experience in the healthcare and technology sectors across the US, UK, and Europe. As the Chief Executive Officer of Ori Biotech, he spearheads the company’s efforts in revolutionizing cell and gene therapy manufacturing technology. Through digital transformation, Ori Biotech’s technology is automating and standardizing cell and gene therapy manufacturing. As a result, their system facilitates an innovative progression from pre-clinical stages to large-scale commercial production for therapy developers. The platform’s advanced hardware, intuitive software, and detailed analytical tools, is designed to boost production efficiency and reliability, all while simultaneously reducing costs. This advancement is pivotal in scaling up the production of critical therapies, facilitating their accessibility to a broader range of patients globally. Jason is also the host of the Ori Spotlight Podcast.
This episode features a conversation with Jason Foster. Jason is a dynamic leader with over 20 years of experience in the healthcare and technology sectors across the US, UK, and Europe. As the Chief Executive Officer of Ori Biotech, he spearheads the company’s efforts in revolutionizing cell and gene therapy manufacturing technology.
Tom Ulrich is a seasoned engineer and engineering manager with over 30 years of experience, a consultant, an Engineering Fellow at Tandem Diabetes, and an Adjunct Professor of Engineering at Biola University. He is also the author of ‘Leading Engineers,’ a book tailored for engineering managers that melds the wisdom accrued from his extensive career in engineering and management with insightful leadership theories from academia.
Max G. Ostermeier (MBA) is the co-founder and General Manager of Implandata Ophthalmic Products GmbH. He brings extensive experience in the commercial development of advanced technologies, building operational capabilities for rapidly growing companies, and creating businesses that attract global acquirers.
As a serial entrepreneur, Max founded and managed Odicrain GmbH, a German medical device start-up that developed a pioneering portable device for the rapid detection of intracranial bleedings, which was acquired by a US-based company in 2007. He also co-founded and served as CEO of Cranium Telemetrics GmbH, a medical technology company specializing in innovative neurosurgical products, which was acquired by a leading US medical device company four years after its founding. Additionally, Max played a key role in establishing a biotech entity for a globally leading fine chemistry company, where he served as General Manager and Vice-President until its acquisition by Sigma Aldrich.
By submitting your email to subscribe, you agree to our Privacy Policy.
